

NEW MEXICO HEALTH ALERT NETWORK (HAN) ALERT **Updated Guidance for RSV Infant Immunization**

September 21, 2026

Background:

This month, the American Academy of Pediatrics (AAP) released updated guidance for the use of RSV monoclonal antibodies.

Recommendations for Clinicians:

The criteria for immunizing infants and children aged 8 to 19 months entering their second RSV season has expanded to include additional clinical conditions. The current list of criteria for the 8–19-month age group entering their second RSV season is now:

- Infants between 8 and 19 months of age at high risk for severe disease and entering their second RSV season regardless of the RSV vaccination status of the birthing parent or the child's prior receipt of nirsevimab or clesrovimab when less than 8 months old in their first RSV season
- Children born preterm, at <32 weeks, 0 day's gestation
- Children with hemodynamically significant congenital heart disease
- Children with anatomic pulmonary abnormalities or neuromuscular disorders that put them at risk for severe RSV disease
- Children with Down syndrome or other chromosomal differences
- American Indian or Alaska Native children
- Children with chronic lung disease attributable to prematurity or other significant neonatal conditions that required medical support at any time during the 6-month period before the start of their second RSV season
- Children with cystic fibrosis who have either manifestation of severe lung disease or weight-for-length that is less than the 10th percentile

The AAP also recommends RSV immunization for:

- Infants less than 8 months old born during or entering their first RSV season if the birthing parent did not receive the RSV vaccination during pregnancy; if the birthing parent's RSV vaccination status is unknown; or, if the infant was born less than 14 days after vaccination of the birthing parent

Access:

Providers enrolled under the Vaccines for Children (VFC) program can order the following presentations to preposition appointments for the season.

Nirsevimab (Beyfortus) 50 mg and 100 mg (5 pack dose packages)

Clesrovimab (Enflonsia) 105 mg (1 pack – single-dose or 10 pack – single dose)

Providers can order supply as needed throughout the season.

Additional Resources:

The complete AAP guidance can be found here: [Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Policy Statement | Pediatrics | American Academy of Pediatrics](#).

NMDOH recommendations: [Immunization Schedules](#)

The [NM Health Viral Respiratory Dashboard](#), updated weekly, provides information regarding the current respiratory season, including RSV hospitalization rates.

Immunization Dashboards:

RSV Infant Coverage Rates [Immunization Dashboards](#)

VFC Provider locator [Immunization Dashboards](#)

All vaccinations for children and adults are required by law to be entered into the New Mexico State Immunization Information System (NMSIIS). If you need access, training, or assistance with using NMSIIS, contact the [NMSIIS](#) Help Desk at 1-833-882-6454.

New Mexico Health Alert Network: To register for the NM Health Alert Network, please visit the following site <https://nm.readyop.com/fs/4cjZ/10b2> Please fill out the registration form completely and click Submit at the bottom of the page, to begin receiving Important health alerts, advisories, and updates.

Please Note that our system also utilizes text messaging to notify members of important health information. Due to FCC Regulation changes that are designed to decrease the amount of unwanted spam text messages sent each year to citizens, please save, this phone number **(855) 596-1810** as the “**New Mexico Health Alert Network**” default phone number for your account used for text messages on the mobile device(s) you register with us.